Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUN ZHANG

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1902175615
CMS profile
1361167
Location
IOWA CITY, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$92,005.50

67 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUN ZHANG

NPI 1902175615 · CMS profile ID 1361167

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

IOWA CITY, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1902175615?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUN ZHANG, NPI 1902175615, CMS profile ID 1361167. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902175615?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JUN ZHANG, NPI 1902175615, CMS profile ID 1361167. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902175615?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JUN ZHANG, NPI 1902175615, CMS profile ID 1361167, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1902175615?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

67 matching records · $92,005.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 67 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–67 of 67.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Pharmaceuticals, Inc. $22.0006/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927752193 CMS
Regeneron Pharmaceuticals, Inc. $694.1206/24/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927752151 CMS
Regeneron Pharmaceuticals, Inc. $35.2506/24/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927752157 CMS
Regeneron Pharmaceuticals, Inc. $35.2506/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927752139 CMS
Regeneron Pharmaceuticals, Inc. $530.9206/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927752145 CMS
AstraZeneca Pharmaceuticals LP $88.4406/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915862471 CMS
Regeneron Healthcare Solutions, Inc. $1,438.0005/12/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927488133 CMS
GENZYME CORPORATION $956.2705/10/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939065397 CMS
Regeneron Healthcare Solutions, Inc. $7.1705/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927488129 CMS
GENZYME CORPORATION $7,190.0004/22/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939065315 CMS
AstraZeneca Pharmaceuticals LP $250.0004/18/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915791387 CMS
GENZYME CORPORATION $80.8904/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939065311 CMS
GENZYME CORPORATION $3,775.0004/13/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939065313 CMS
Novartis Pharmaceuticals Corporation $2,025.0004/05/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894883851 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,295.0003/04/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955888061 CMS
AstraZeneca Pharmaceuticals LP $1,350.0002/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915221023 CMS
AstraZeneca Pharmaceuticals LP $1,350.0002/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915828277 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,699.56 12
PY2020 $19,639.97 13
PY2021 $33,532.75 18
PY2022 $92,005.50 67
PY2023 $75,896.14 59
PY2024 $71,860.14 64
PY2025 $76,055.17 54

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $814,320.58 71
PY2024 Recipient $3,423.96 1
PY2024 Principal investigator $2,234,252.99 201
PY2023 Principal investigator $2,744,437.72 180
PY2022 Principal investigator $795,242.05 55
PY2021 Recipient $11,250.00 1
PY2021 Principal investigator $958,787.12 7
PY2020 Principal investigator $11,915.34 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

71 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $639.58 12/11/2025 Non-covered Recipient Entity
University Of Kansas Health System Clinical Research Center
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220698025
Principal investigator 1 Genentech, Inc. $16,758.00 11/10/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Ipat and taxane in NSCLC No dispute reported 06/30/2026 1211678065
Principal investigator 1 AstraZeneca Pharmaceuticals LP $103,071.84 11/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF KANSAS HEALTH SYSTEM
Using microbiome to predict durvalumab toxicity in post-CCRT NSCLC patients No dispute reported 06/30/2026 1185537643
Principal investigator 1 Eli Lilly and Company $12,896.00 10/20/2025 Non-covered Recipient Entity
UNIV OF KANSAS MED CNTR RSRCH INSTITUTE
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 No dispute reported 06/30/2026 1187891826
Principal investigator 1 Eli Lilly and Company $15,031.00 10/14/2025 Non-covered Recipient Entity
UNIV OF KANSAS MED CNTR RSRCH INSTITUTE
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187893218
Principal investigator 1 ABBVIE INC. $267.00 09/30/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202512788
Principal investigator 1 ABBVIE INC. $400.00 09/23/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202511864
Principal investigator 1 ABBVIE INC. $15,511.23 09/04/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202508646
Principal investigator 1 Janssen Research & Development, LLC $9,931.00 09/04/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175379971
Principal investigator 1 Janssen Research & Development, LLC $568.00 08/29/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175379941
Principal investigator 1 ABBVIE INC. $267.00 08/27/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202506027
Principal investigator 1 Janssen Research & Development, LLC $3,122.00 08/22/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175379824
Principal investigator 1 Janssen Research & Development, LLC $7,436.00 08/20/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175379873
Principal investigator 1 Janssen Research & Development, LLC $5,950.00 07/28/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175379978
Principal investigator 1 Janssen Research & Development, LLC $2,772.00 07/28/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175380082
Principal investigator 1 ABBVIE INC. $534.00 07/24/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202499670
Principal investigator 1 Janssen Research & Development, LLC $6,862.00 07/24/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175379923
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,525.00 07/17/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220811804
Principal investigator 1 Genentech, Inc. $29,326.50 07/17/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Ipat and taxane in NSCLC No dispute reported 06/30/2026 1211678057
Principal investigator 1 Mirati Therapeutics, Inc. $4,179.66 07/11/2025 Non-covered Recipient Entity
Kumc Research Institute, Incorporated
A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1236531028
Principal investigator 1 ABBVIE INC. $3,962.21 07/09/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202497688
Principal investigator 1 ABBVIE INC. $1,455.56 07/02/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202496521
Principal investigator 1 ABBVIE INC. $15,014.35 07/02/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202496619
Principal investigator 1 ABBVIE INC. $267.00 07/01/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202493843
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $13.30 06/24/2025 Non-covered Recipient Entity
University Of Kansas Health System Clinical Research Center
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220996622
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $7.10 06/24/2025 Non-covered Recipient Entity
University Of Kansas Health System Clinical Research Center
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220996624
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1.55 06/24/2025 Non-covered Recipient Entity
University Of Kansas Health System Clinical Research Center
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220996626
Principal investigator 1 Janssen Research & Development, LLC $8,659.00 06/23/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175379908
Principal investigator 1 Janssen Research & Development, LLC $8,763.00 06/20/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175379766
Principal investigator 1 ABBVIE INC. $426.94 06/18/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202492079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33,266.50 06/12/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184206713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 06/12/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184206715
Principal investigator 1 ABBVIE INC. $94.79 06/11/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202490831
Principal investigator 1 AstraZeneca Pharmaceuticals LP $101,050.80 06/11/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER CYSTIC FIBROSIS PROGRAM
Using microbiome to predict durvalumab toxicity in post-CCRT NSCLC patients No dispute reported 06/30/2026 1185537645
Principal investigator 1 ABBVIE INC. $267.00 06/05/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202490337
Principal investigator 1 ABBVIE INC. $7,865.42 06/03/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202487395
Principal investigator 1 Janssen Research & Development, LLC $241.00 05/30/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175379949
Principal investigator 1 Janssen Research & Development, LLC $5,579.00 05/29/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175379987
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $81.62 05/27/2025 Non-covered Recipient Entity
University Of Kansas Health System Clinical Research Center
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220996614
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $59.94 05/27/2025 Non-covered Recipient Entity
University Of Kansas Health System Clinical Research Center
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220996616
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $146.00 05/27/2025 Non-covered Recipient Entity
University Of Kansas Health System Clinical Research Center
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220996618
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2.76 05/27/2025 Non-covered Recipient Entity
University Of Kansas Health System Clinical Research Center
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220996620
Principal investigator 1 Janssen Research & Development, LLC $12,129.00 05/22/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175379816
Principal investigator 1 AstraZeneca Pharmaceuticals LP $48,686.04 05/18/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER ANESTHESIOLOGY
Using microbiome to predict durvalumab toxicity in post-CCRT NSCLC patients No dispute reported 06/30/2026 1185537641
Principal investigator 1 Janssen Research & Development, LLC $346.00 05/12/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175379783
Principal investigator 1 Janssen Research & Development, LLC $1,687.00 05/12/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175380037
Principal investigator 1 Janssen Research & Development, LLC $773.00 05/12/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175380067
Principal investigator 1 Janssen Research & Development, LLC $1,737.00 05/12/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175380147
Principal investigator 1 ABBVIE INC. $736.93 05/08/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202484385
Principal investigator 1 ABBVIE INC. $8,960.75 05/07/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202483065
Principal investigator 1 Janssen Research & Development, LLC $4,290.00 04/28/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175380028
Principal investigator 1 Janssen Research & Development, LLC $9,413.00 04/25/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175380125
Principal investigator 1 Janssen Research & Development, LLC $3,640.00 04/25/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175380140
Principal investigator 1 Janssen Research & Development, LLC $8,508.00 04/24/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175380021
Principal investigator 1 Mirati Therapeutics, Inc. $34,957.63 04/16/2025 Non-covered Recipient Entity
Kumc Research Institute, Incorporated
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236531020
Principal investigator 1 BeiGene, Ltd. $96.12 04/11/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190320738
Principal investigator 1 ABBVIE INC. $14,943.82 04/08/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202474998
Principal investigator 1 ABBVIE INC. $4,030.83 04/03/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202472479
Principal investigator 1 Janssen Research & Development, LLC $3,184.00 03/24/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175380091
Principal investigator 1 Janssen Research & Development, LLC $8,625.00 03/20/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175379775
Principal investigator 1 Genentech, Inc. $1,425.00 03/14/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
Tira atzo with or without chemo in neoadjuvant NSCLC No dispute reported 06/30/2026 1211677934
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 03/10/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175379724
Principal investigator 1 Janssen Research & Development, LLC $3,640.00 03/10/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175379996
Principal investigator 1 ABBVIE INC. $18,576.91 03/07/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
M23-721 - Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202461083
Principal investigator 1 Mirati Therapeutics, Inc. $22,385.38 03/03/2025 Non-covered Recipient Entity
Kumc Research Institute, Incorporated
A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutatio No dispute reported 06/30/2026 1236531024
Principal investigator 1 Mirati Therapeutics, Inc. $139,003.82 03/03/2025 Non-covered Recipient Entity
Kumc Research Institute, Incorporated
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236531035
Principal investigator 1 Janssen Research & Development, LLC $17,391.00 02/20/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175379882
Principal investigator 1 ABBVIE INC. $400.00 02/18/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
M23-721 - Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202452272
Principal investigator 1 ABBVIE INC. $5,738.79 02/06/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
M23-721 - Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202448167
Principal investigator 1 Eli Lilly and Company $284.91 02/03/2025 Non-covered Recipient Entity
STATE OF KANSAS/UNIVERSITY OF KANSAS MEDICAL CENTER
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187889704
Principal investigator 1 Janssen Research & Development, LLC $4,958.00 01/20/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175379955